OPAXIO

OPAXIO (formerly XYOTAX) is an underdevelopment drug used in chemotherapy. This paclitaxel-based drug reduces the amount of time paclitaxel chemotherapy takes, decreases the chance that a patient will have an allergic response to the treatment, and minimizes potential paclitaxel side effects. Cell Therapeutics, Inc. (CTI), the company developing Xyotax, has placed its focus on finding ways to make current cancer drugs more effective and less toxic.

What is OPAXIO?

Knowing that tumor blood vessels are more permeable to large molecules than normal blood vessels, OPAXIO developers reformulated paclitaxel in such a way that it would be absorbed and trapped by tumor tissue but not by normal tissue. The cancer targeting abilities of OPAXIO make it more effective and less toxic than paclitaxel alone.

OPAXIO has been granted "fast track designation" by the FDA for the treatment of "poor performance status" patients with advanced non-small cell lung cancer. The FDA expedites the approval process for certain drugs because they "address unmet medical needs," and "treat serious or life threatening conditions."

OPAXIO May Reduce Paclitaxel Side Effects

OPAXIO, if approved, may significantly reduce the side effects of paclitaxel, which includes a reduction in red and white blood cells, infection, hair loss, allergic reactions, and nausea.

Locate a Lung Cancer Attorney in Your Area

If you or someone you love has developed lung, it is important for you to speak with an experienced lung cancer lawyer to learn about your legal entitlements. Use our legal directory to locate a lung cancer lawyer in your state.